Inhibition of cell signalling pathways.
Langdon
S P
SP
Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh, U.K.
Smyth
J F
JF
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D017978:Receptors, Growth Factor / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D006133:Growth Substances; D017978:Receptors, Growth Factor